State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Vaxcyte Inc. Common Stock — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77 (market cap $3.10B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 3.4× State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 17 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| FLRN | PCVX | |
|---|---|---|
Market Cap | $3.10B | $10.51B |
Volume | 1,095,314 | 2,644,694 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $73.82 |
52-Week Low | $30.65 | $40.32 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | — | $9.14B |
Signals from Pluang's Aura AI — not financial advice
FLRN, the SPDR Bloomberg Investment Grade Floating Rate ETF, trades at $30.77 with no recent price change. Technical indicators signal a bearish trend, while recent news highlights its appeal as a floating-rate bond ETF amid rising interest rates. The ETF has announced several small dividends for 2026, but key financial ratios like P/E and P/B are unavailable.
The outlook for FLRN is mixed; its near-zero duration and floating-rate structure offer protection against rate hikes, attracting institutional interest. However, significant financial sector exposure and bearish technical signals pose risks. Investors should weigh the defensive characteristics against market volatility and sector-specific headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →